Navigation Links
Drug trials funded by industry are more likely to publish favorable results
Date:8/2/2010

Boston, Mass. -- When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favorable to the drug in question, report researchers at Children's Hospital Boston. Publishing in the August 3 issue of the Annals of Internal Medicine, the researchers call for more public disclosure about clinical drug trials at their outset to reduce the possibility of bias in the findings.

The research team, led by Florence Bourgeois, MD, MPH, of Children's Division of Emergency Medicine, and Kenneth Mandl, MD, MPH, Laboratory Director in the Children's Hospital Informatics Program, reviewed 546 drug trials conducted between 2000 and 2006 and listed with ClinicalTrials.gov, a comprehensive, web-based federal registry of clinical trials. The analysis focused on five classes of drugs: cholesterol-lowering drugs, antidepressants, antipsychotics, proton-pump inhibitors and vasodilators. The researchers scanned the medical literature for publications associated with each trial, checking four separate databases and contacting trial investigators directly if necessary.

Overall, allowing for a three-year lag time from the completion of the trial, two-thirds of the trials had published results. The industry-funded trials reported positive outcomes 85 percent of the time, as compared with 50 percent for government-funded trials and 72 percent for trials funded by nonprofits or non-federal organizations. In addition, among the nonprofit/nonfederal trials, those that had industry contributions (nearly half) were more likely than those without to report positive outcomes (85 vs. 61 percent). These differences were all statistically significant.

The researchers acknowledge that the pharmaceutical industry was probably more selective in which trials it funded, helping to account for their greater proportion of favorable outcomes. "Industry is very good at knowing what they want to study, and industry-sponsored studies are more efficient and well funded," says Bourgeois, the study's first author. "But despite these potential biases, this is a stunning result."

The industry-funded trials were in more advanced phases of study; 89 percent were Phase 3 or Phase 4, versus just 51 percent of government-funded trials and 65 percent of nonprofit/nonfederally-funded trials. However, even Phase 1 and 2 trials funded by industry reported the highest percentage of favorable outcomes.

In addition, industry-funded trials were the least likely to have published results within two years of study completion (32 percent) as compared with trials with no industry contributions (54 percent for government trials, and 56 percent for purely nonprofit/nonfederal trials).

As the researchers discuss in the paper, clinical trials can be manipulated in various ways to make the results appear more favorable. Publication bias a tendency to selectively publish only positive results of a trial, or delay publication of negative results is one factor that has received much attention, as in a well-publicized 2008 study of antidepressants in The New England Journal of Medicine.

"While we cannot specifically point to which factors contribute to the association between funding source and positive result reporting, our findings speak to the need for more disclosure of all elements of a study," says Bourgeois. "Publication bias is likely a contributing factor, but there may be many more, including biases in study design, patient selection, data analysis and results reporting."

The use of registries like ClinicalTrials.gov, launched in 1999, was hoped to reduce publication bias by creating a record for all clinical trials. In addition, in 2005, the International Committee of Medical Journal Editors began requiring that a trial be registered before enrolling patients in order to be considered for publication, thus creating a record of the planned study outcomes before the study's initiation. In 2007, the FDA expanded the scope of Clinical Trials.gov, requiring the sponsors of all drug, biologic and device trials to register their studies upon launch (phase I trials excepted).

If trial protocols are made public in advance, a trial sponsor is less able to manipulate or selectively publish the findings, the researchers argue. "Our main call is for transparency, to enable better understanding of the impact of funding source on the study outcomes, and for all study results good or bad to be made available," says Mandl, the study's senior investigator, also an Associate Professor at Harvard Medical School.


'/>"/>

Contact: Keri Stedman
keri.stedman@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. Clinical trials can be improved by managing the learning curve
2. Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials
3. Hopkins faculty lead development of report to FDA on ethical, scientific issues related to post-market clinical trials
4. Announcing: Intrinsic Imaging : Radiology Experts Launch Novel Medical Imaging CRO for Clinical Trials
5. US Department of Defense helps move spinal cord injury treatment closer to clinical trials
6. Second Ohio State cancer drug begins clinical trials testing
7. Compound enhances cancer-killing properties of agent in trials
8. Newer Drugs Beat Gleevec in Head-to-Head Trials
9. Nicer than needles: Insulin pills for diabetes finally in clinical trials
10. Trials begin on potent new hepatitis C drug
11. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... "Add realistic flares ... flicker, flash, and flare from clip to clip with high quality 4K lens flare ... 4K Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon ...
(Date:12/5/2016)... , ... December 05, 2016 , ... What: Shriners Hospitals ... the North Pole to our patients – using a video monitor and web-enabled camera. ... hospital will transform the Auditorium into a Christmas Wonderland, which is where the video ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 ... the Lithuanian language and its poetry inspired him in writing “ Forest ... all aspects of a living, breathing forest where nothing ever stays the same. His ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted from ... Executive® (ISE®) Central Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: